Xencor to Host Third Quarter 2016 Financial Results Webcast and Conference...
(Source: Xencor Inc) MONROVIA, Calif., Oct. 26, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor to Present at Upcoming Investor Conferences (Xencor Inc)
(Source: Xencor Inc) MONROVIA, Calif., Oct. 31, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor to Present at Leerink Partners 6th Annual Global Healthcare Conference...
(Source: Xencor Inc) MONROVIA, Calif., Feb. 9, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View ArticleXencor to Present at Oppenheimer 27th Annual Healthcare Conference
MONROVIA, Calif., March 15, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleIgG4-Related Disease Biomarker Development Update Presented From an Ongoing,...
(Source: Xencor Inc) MONROVIA, Calif., Feb. 18, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleIgG4-Related Disease Biomarker Development Update Presented From an Ongoing,...
MONROVIA, Calif., Feb. 18, 2017 /PRNewswire/ -- Xencor, Inc. XNCR, +2.10% a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticlePreliminary Data from the Ongoing Open-Label XmAb5871 Phase 2 Pilot Study in...
(Source: Xencor Inc) MONROVIA, Calif., Oct. 3, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View ArticleXencor Initiates Phase 1b Trial of Subcutaneous Formulation of XmAb7195...
(Source: Xencor Inc) MONROVIA, Calif., Sept. 15, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor Presents Preclinical Data on XmAb20717 Dual Checkpoint Blockade and...
(Source: Xencor Inc) MONROVIA, Calif., Nov. 11, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor Appoints Yujiro S. Hata to Board of Directors
MONROVIA, Calif., July 31, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor Reports Complete Data Results on XmAb5871 Program at European League...
MONROVIA, Calif., June 10, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor's (XNCR) CEO Bassil Dahiyat on Q3 2016 Results - Earnings Call Transcript
Xencor, Inc. (NASDAQ:XNCR) Q3 2016 Earnings Conference Call November 02, 2016 4:30 PM ET Executives Hannah Deresiewicz - Stern Investor Relations Bassil Dahiyat – President, Chief Executive Officer and...
View ArticleXencor Initiates Two Phase 2 Trials of XmAb5871 in IgG4-Related Disease and...
MONROVIA, Calif., March 7, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor Appoints Yujiro S. Hata to Board of Directors (Xencor Inc)
(Source: Xencor Inc) MONROVIA, Calif., July 31, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor Reports Complete Data Results on XmAb5871 Program at European League...
(Source: Xencor Inc) MONROVIA, Calif., June 10, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor Initiates Two Phase 2 Trials of XmAb5871 in IgG4-Related Disease and...
(Source: Xencor Inc) MONROVIA, Calif., March 7, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor's XmAb®5871 Program to be Featured in Poster Presentation at European...
(Source: Xencor Inc) MONROVIA, Calif., May 11, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View ArticleXencor, Inc. Appoints Mark Lotz, R.Ph., as Vice President of Regulatory...
MONROVIA, Calif., May 13, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor, Inc. Appoints Mark Lotz, R.Ph., as Vice President of Regulatory...
MONROVIA, Calif., May 13, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor, Inc. Appoints Mark Lotz, R.Ph., as Vice President of Regulatory...
(Source: Xencor Inc) MONROVIA, Calif., May 13, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View Article